Q2 EPS Estimate for Soleno Therapeutics Increased by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a research report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.00 per share for the quarter, up from their previous forecast of $0.85. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q3 2026 earnings at $1.24 EPS and Q4 2026 earnings at $1.70 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million.

Several other research firms have also recently issued reports on SLNO. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Wednesday, October 8th. The Goldman Sachs Group set a $125.00 target price on shares of Soleno Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Zacks Research upgraded Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research note on Monday, January 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $110.62.

Soleno Therapeutics Trading Up 2.9%

Soleno Therapeutics stock opened at $43.73 on Wednesday. The firm has a market cap of $2.35 billion, a PE ratio of -23.77 and a beta of -3.12. Soleno Therapeutics has a 12 month low of $39.43 and a 12 month high of $90.32. The stock’s 50 day simple moving average is $47.40 and its two-hundred day simple moving average is $61.82. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust increased its position in shares of Soleno Therapeutics by 9.1% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 405,651 shares of the company’s stock worth $33,985,000 after purchasing an additional 33,954 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Soleno Therapeutics by 255.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 280,984 shares of the company’s stock worth $18,995,000 after purchasing an additional 201,983 shares during the last quarter. Castleark Management LLC acquired a new stake in Soleno Therapeutics during the 2nd quarter worth $2,919,000. TD Asset Management Inc grew its holdings in shares of Soleno Therapeutics by 34.9% during the second quarter. TD Asset Management Inc now owns 99,810 shares of the company’s stock worth $8,362,000 after buying an additional 25,800 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Soleno Therapeutics by 62.0% in the second quarter. Rhumbline Advisers now owns 59,046 shares of the company’s stock valued at $4,947,000 after buying an additional 22,607 shares during the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.